CRSP - CRISPR Therapeutics AG
60
1.940 3.233%
Share volume: 1,170,589
Last Updated: 03-04-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.44%
PREVIOUS CLOSE
CHG
CHG%
$58.06
1.94
0.03%
Fundamental analysis
5%
Profitability
0%
Dept financing
5%
Liquidity
50%
Performance
0%
Performance
5 Days
-1.27%
1 Month
30.78%
3 Months
5.49%
6 Months
9.37%
1 Year
36.86%
2 Year
-25.92%
Key data
Stock price
$60.00
DAY RANGE
$57.75 - $60.60
52 WEEK RANGE
$30.04 - $78.48
52 WEEK CHANGE
$38.54
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-04-2025
Company detail
CEO: Samarth Kulkarni
Region: US
Website: crisprtx.com
Employees: 460
IPO year: 2016
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
Region: US
Website: crisprtx.com
Employees: 460
IPO year: 2016
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Biological Products, Except Diagnostic Substances
Sector: Manufacturing
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases. The company's lead product candidate is CTX001, an ex-viggered therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies.
Recent news